oxymorphone (opana) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Oxymorphone is an analgesic that is FDA approved for the treatment of moderate to severe pain. It is also indicated for relief of anxiety in patients with dyspnea associated with pulmonary edema secondary to acute left ventricular dysfunction. Oxymorphone (brand names Opana, Numorphan, Numorphone) is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. Adverse reactions (≥ 2% of patients): seen with the immediate release tablet formulation Nausea, pyrexia, somnolence, vomiting, pruritus, headache, dizziness, constipation, and confusion. Concomitant use with serotonergic drugs may result in serotonin syndrome. Avoid use of mixed agonist/antagonist and partial agonist opioid analgesics with Opana because they may reduce analgesic effect of Opana or precipitate withdrawal symptoms.   NCATS

Chemistry

  • SMILES: CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
  • InChIKey: UQCNKQCJZOAFTQ-ISWURRPUSA-N
  • Mol. Mass: 301.34
  • ALogP: 0.75
  • ChEMBL Molecules:
    oxymorphone  
    oxymorphone hydrochloride  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.2499 - $15.4795
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

14-hydroxydihydromorphinone | dihydrohydroxymorphinone | en3202 | numorphan | opana | opana er | oximorphonum | oxymorphine | oxymorphone | (-)-oxymorphone | oxymorphone hcl | oxymorphone hydrochloride

Organizations (27)

Research & Development (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (15)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (4)


 

Acute Pain

Anxiety (approved 1959)

Pain

Pain, Postoperative

Experimental Indications - Clinical Trial Phases 1-4 (14)


 

Acute Pain (Phase 3)

Cancer Pain (Phase 3)

Chronic Disease (Phase 3)

Chronic Pain (Phase 4)

Healthy Volunteers (Phase 4)

Low Back Pain (Phase 3)

Narcotic-Related Disorders (Phase 4)

Neoplasms (Phase 3)

Neuralgia (Phase 3)

Opioid-Related Disorders (Phase 4)

Pain ()

Pain, Postoperative (Phase 3)

Spinal Stenosis (Phase 4)

Substance-Related Disorders (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 25
  • # of Trial Organizations: 13

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue